. 2023 Mar 9;51(3):03000605231159333. doi: 10.1177/03000605231159333

Table 1.

Basic characteristics of included studies.

Study	Country	Follow-up	Patients in placebo vs. vericiguat groups	NYHA class	Ejection fraction	Dose of vericiguat (mg)	Cardiovascular-related deaths (event:total)		HF hospitalizations (event:total)		Adverse events (event:total)
Study	Country	Follow-up	Patients in placebo vs. vericiguat groups	NYHA class	Ejection fraction	Dose of vericiguat (mg)	placebo	vericiguat	placebo	vericiguat	placebo	vericiguat
Gheorghiade et al.¹⁰	Europe, North America, and Asia	16 weeks	92: 364	II–IV	<45%	1.5, 2.5, 5, 10	6:92	15:364	16:92	50:364	71:92	267:363
Armstrong et al.¹¹	42 countries	12 months	2515:2519	I–IV	<45%	10	225:2515	206:2519	747:2519	691:2515	2027:2519	2036:2515
Pieske et al.¹²	25 countries	12 weeks	93:334	II–IV	≥45%	1.5, 2.5, 5, 10	1:93	1:334	NA	NA	68:93	379:525
Armstrong et al.¹³	21 countries	24 weeks	262: 526	II–III	≥45%	10, 15	4:262	20:526	NA	NA	172:262	335:526

NYHA, New York Heart Association; HF, heart failure; NA, not available.